Vidaza® Improves Survival in Higher-risk Myelodysplastic Syndromes (03/06/2009)
According to the results of a Phase III clinical trial, treatment with Vidaza® (azacitidine) results in better survival than conventional care among patients with higher-risk myelodysplastic syndromes (MDS). These results were published in Lancet Oncology.

The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies (01/30/2009)
The 2008 annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois, again revealed advances in the treatment of hematologic malignancies. Patients with chronic or acute leukemias, myelodysplastic syndromes, and myeloproliferative disorders continue to be presented with novel, effective options for the treatment of their diseases.

New Risk Model for MDS Applies to All Stages of Disease (12/31/2008)
A new risk model for myelodysplastic syndrome (MDS) provides survival projections for all stages of the disease and has proven superior to the International Prognostic Scoring System (IPSS) that has been traditionally used. The results of this study were presented at the annual meeting of the American Society of Hematology on December 8, 2008 in San Francisco, California.

Older Age Does Not Affect Survival in Patients with AML or MDS Who Undergo Mini-transplants (12/30/2008)
Age should not be a barrier for non-myeloablative allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), according to the results of a study presented at the 50^th Annual Meeting of the American Society of Hematology on December 7, 2008 in San Francisco, California.

Vidaza® Approved for High-risk MDS (08/22/2008)
The US Food and Drug Administration (FDA) has approved Vidaza® (azacitadine) for the treatment of high-risk myelodysplastic syndromes. Vidaza is already approved for MDS that is categorized into all five French American British (FAB) subtypes. This information was recently released in a press release by Celgene Corporation.

▪ More...

Vidaza® Improves Survival in Higher-risk Myelodysplastic Syndromes (03/06/2009)
According to the results of a Phase III clinical trial, treatment with Vidaza® (azacitidine) results in better survival than conventional care among patients with higher-risk myelodysplastic syndromes (MDS). These results were published in Lancet Oncology.

The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies (01/30/2009)
The 2008 annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois, again revealed advances in the treatment of hematologic malignancies. Patients with chronic or acute leukemias, myelodysplastic syndromes, and myeloproliferative disorders continue to be presented with novel, effective options for the treatment of their diseases.

New Risk Model for MDS Applies to All Stages of Disease (12/31/2008)
A new risk model for myelodysplastic syndrome (MDS) provides survival projections for all stages of the disease and has proven superior to the International Prognostic Scoring System (IPSS) that has been traditionally used. The results of this study were presented at the annual meeting of the American Society of Hematology on December 8, 2008 in San Francisco, California.

Older Age Does Not Affect Survival in Patients with AML or MDS Who Undergo Mini-transplants (12/30/2008)
Age should not be a barrier for non-myeloablative allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), according to the results of a study presented at the 50^th Annual Meeting of the American Society of Hematology on December 7, 2008 in San Francisco, California.

Vidaza® Approved for High-risk MDS (08/22/2008)
The US Food and Drug Administration (FDA) has approved Vidaza® (azacitadine) for the treatment of high-risk myelodysplastic syndromes. Vidaza is already approved for MDS that is categorized into all five French American British (FAB) subtypes. This information was recently released in a press release by Celgene Corporation.

▪ More...